Table 1.

Significant randomized, placebo-controlled studies of different SGLT2 inhibitors as an add-on therapy to insulin in adults with type 1 diabetes

Study	SGLT2 Inhibitor (mg)	Duration (weeks)	HbA1ca (%)	Time in rangea 3.9–10 mmol/L (70–180 mg/dL) (%)	DKA (%)
					SGLT2 inhibitor	Placebo
Henry et al. [33]	Canagliflozin 100	18	−0.29	−	4.3	0
	Canagliflozin 300		−0.25		6.0
DEPICT-1 [34, 40]	Dapagliflozin 5	52	−0.33	+9.1	4.0	1.9
	Dapagliflozin 10		−0.36	+10.7	3.4
DEPICT-2 [39, 41]	Dapagliflozin 5	52	−0.20	+9.0	4.1	0.4
	Dapagliflozin 10		−0.25	+10.7	3.7
inTandem1 [35]	Sotagliflozin 200	52	−0.25	+3.0	3.4	0.4
	Sotagliflozin 400		−0.31	+10.4	4.2
inTandem2 [36]	Sotagliflozin 200	52	−0.21	+8.4	2.3	0
	Sotagliflozin 400		−0.32	+13.4	3.4
inTandem3 [37]	Sotagliflozin 400	24	−0.46	−	3.0	0.6
EASE-2 [38]	Empagliflozin 10	52	−0.39	+12.2	4.3b	1.2
	Empagliflozin 25		−0.45	+12.5	3.3b
EASE-3 [38]	Empagliflozin 2.5	26	−0.28	+4.3	0.8
	Empagliflozin 10		−0.45	+10.7	−
	Empagliflozin 25		−0.52	+7.4	−

SGLT2, sodium-glucose co-transporter-2; HbA1c, glycated haemoglobin; DKA, diabetic ketoacidosis.

^aRelative to placebo.

^bPooled data for both EASE-2 and EASE-3 studies.